This meeting will look at how better Clinical Candidates can be designed with an enhanced awareness of potential future safety issues.
Following the focus on pharmacokinetics and drug metabolism in the discovery process during the 1990's, the causes of attrition have shifted, with drug toxicity now accounting for a significant proportion of drug failures. This has led to an increased focus on developing improved preclinical safety screening strategies and compound design principles and this meeting will provide practical insights into some of the recent improvements and future directions in this key area.
Following the focus on pharmacokinetics and drug metabolism in the discovery process during the 1990's, the causes of attrition have shifted, with drug toxicity now accounting for a significant proportion of drug failures. This has led to an increased focus on developing improved preclinical safety screening strategies and compound design principles and this meeting will provide practical insights into some of the recent improvements and future directions in this key area.
